Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PRPO Stock Summary
In the News
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year.
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.
Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q1 2023 Earnings Conference Call May 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio, Inc. (PRPO) Q3 2022 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Shareholder Third Quarter 2022 Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Operator Welcome to the Precipio Shareholder -- Second Quarter 2022 Shareholder Update Conference Call. (Operator Instructions) Please note that the conference is being recorded.
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College , organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans.
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2021 Results - Earnings Call Transcript
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2021 Results - Earnings Call Transcript
PRPO Financial details
PRPO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 39.75 | 10.98 | 7.39 | 8.39 | 8.27 | |
Net income per share | -217.81 | -46.51 | -14.84 | -8.1 | -10.73 | |
Operating cash flow per share | -93.73 | -32.1 | -9.02 | -6.23 | -6.79 | |
Free cash flow per share | -95.08 | -32.29 | -9.21 | -6.88 | -7.03 | |
Cash per share | 5.29 | 2.98 | 3.22 | 11.06 | 3.03 | |
Book value per share | 84.98 | 46.37 | 17.16 | 23.29 | 14.33 | |
Tangible book value per share | -182.75 | -12.13 | -1.83 | 9.37 | 2.28 | |
Share holders equity per share | 84.98 | 46.37 | 17.16 | 23.29 | 14.33 | |
Interest debt per share | 48.69 | 6.43 | 2.38 | 1.37 | 1.23 | |
Market cap | 3.33M | 11.68M | 34.11M | 33.34M | 12.54M | |
Enterprise value | 8.05M | 12.19M | 32.94M | 23.1M | 10.48M | |
P/E ratio | -0.21 | -0.88 | -2.79 | -3.9 | -1.03 | |
Price to sales ratio | 1.16 | 3.73 | 5.6 | 3.77 | 1.33 | |
POCF ratio | -0.49 | -1.28 | -4.59 | -5.07 | -1.62 | |
PFCF ratio | -0.49 | -1.27 | -4.5 | -4.59 | -1.57 | |
P/B Ratio | 0.54 | 0.88 | 2.41 | 1.36 | 0.77 | |
PTB ratio | 0.54 | 0.88 | 2.41 | 1.36 | 0.77 | |
EV to sales | 2.81 | 3.9 | 5.41 | 2.61 | 1.11 | |
Enterprise value over EBITDA | -2.52 | -1.9 | -4.95 | -2.83 | -0.93 | |
EV to operating cash flow | -1.19 | -1.33 | -4.43 | -3.51 | -1.36 | |
EV to free cash flow | -1.18 | -1.33 | -4.34 | -3.18 | -1.31 | |
Earnings yield | -4.71 | -1.13 | -0.36 | -0.26 | -0.97 | |
Free cash flow yield | -2.06 | -0.79 | -0.22 | -0.22 | -0.64 | |
Debt to equity | 0.83 | 0.1 | 0.11 | 0.06 | 0.09 | |
Debt to assets | 0.24 | 0.07 | 0.07 | 0.05 | 0.06 | |
Net debt to EBITDA | -1.48 | -0.08 | 0.18 | 1.25 | 0.18 | |
Current ratio | 0.13 | 0.43 | 0.9 | 3.2 | 1.31 | |
Interest coverage | 8.71 | -19.88 | -19.46 | -480.65 | -1.07K | |
Income quality | 0.43 | 0.69 | 0.7 | 0.77 | 0.63 | |
Dividend Yield | 0 | 0.32 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.28 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.3 | 2.66 | 1.48 | 1.2 | 1.44 | |
Research and developement to revenue | 0 | 0.38 | 0.2 | 0.15 | 0.18 | |
Intangibles to total assets | 0.89 | 0.85 | 0.76 | 0.48 | 0.64 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.02 | 0.1 | 0.04 | |
Capex to revenue | -0.03 | -0.02 | -0.02 | -0.08 | -0.03 | |
Capex to depreciation | -0.08 | -0.04 | -0.11 | -0.47 | -0.18 | |
Stock based compensation to revenue | 0.18 | 0.21 | 0.12 | 0.21 | 0.4 | |
Graham number | 645.32 | 220.28 | 75.7 | 65.16 | 58.81 | |
ROIC | -1.19 | -0.61 | -0.66 | -0.35 | -0.69 | |
Return on tangible assets | -6.78 | -4.64 | -2.42 | -0.54 | -1.58 | |
Graham Net | -201.03 | -17.33 | -3.72 | 6.29 | -0.49 | |
Working capital | -11.97M | -2.46M | -452K | 9.27M | 1.35M | |
Tangible asset value | -13.17M | -3.45M | -1.51M | 9.89M | 2.6M | |
Net current asset value | -13.69M | -4.43M | -2.35M | 7.64M | 573K | |
Invested capital | 0.83 | 0.1 | 0.11 | 0.06 | 0.09 | |
Average receivables | 710K | 632K | 724K | 785.5K | 866.5K | |
Average payables | 5.14M | 3.55M | 1.81M | 1.78M | 1.95M | |
Average inventory | 179K | 190.5K | 267K | 457K | 636K | |
Days sales outstanding | 87.94 | 67 | 52.37 | 28.75 | 40.18 | |
Days payables outstanding | 714.92 | 243 | 125.04 | 105.31 | 107.99 | |
Days of inventory on hand | 27.25 | 23.09 | 25.85 | 31.88 | 37.44 | |
Receivables turnover | 4.15 | 5.45 | 6.97 | 12.7 | 9.08 | |
Payables turnover | 0.51 | 1.5 | 2.92 | 3.47 | 3.38 | |
Inventory turnover | 13.4 | 15.8 | 14.12 | 11.45 | 9.75 | |
ROE | -2.56 | -1 | -0.87 | -0.35 | -0.75 | |
Capex per share | -1.35 | -0.19 | -0.18 | -0.65 | -0.24 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.95 | 2.1 | 2.43 | 2.9 | 2.68 | |
Net income per share | -2.74 | -2.02 | -2.62 | -1.88 | -1.04 | |
Operating cash flow per share | -1.97 | -1.31 | -1.36 | -0.99 | -0.64 | |
Free cash flow per share | -2.07 | -1.36 | -1.38 | -1.01 | -0.66 | |
Cash per share | 4.52 | 3.02 | 1.84 | 2.11 | 1.12 | |
Book value per share | 15.98 | 14.29 | 12.2 | 11.51 | 9.28 | |
Tangible book value per share | 3.73 | 2.28 | 0.6 | 0.66 | -0.04 | |
Share holders equity per share | 15.98 | 14.29 | 12.2 | 11.51 | 9.28 | |
Interest debt per share | 1.4 | 1.23 | 1.03 | 0.88 | 0.92 | |
Market cap | 18.3M | 12.57M | 15.41M | 9.5M | 7.82M | |
Enterprise value | 14.74M | 10.52M | 14.47M | 8M | 7.56M | |
P/E ratio | -1.47 | -1.36 | -1.27 | -1.04 | -1.34 | |
Price to sales ratio | 8.26 | 5.26 | 5.47 | 2.69 | 2.09 | |
POCF ratio | -8.17 | -8.38 | -9.79 | -7.9 | -8.73 | |
PFCF ratio | -7.76 | -8.1 | -9.65 | -7.7 | -8.51 | |
P/B Ratio | 1.01 | 0.77 | 1.09 | 0.68 | 0.6 | |
PTB ratio | 1.01 | 0.77 | 1.09 | 0.68 | 0.6 | |
EV to sales | 6.66 | 4.4 | 5.14 | 2.26 | 2.02 | |
Enterprise value over EBITDA | -5.19 | -5.37 | -5.47 | -4.18 | -5.22 | |
EV to operating cash flow | -6.58 | -7.01 | -9.19 | -6.65 | -8.43 | |
EV to free cash flow | -6.25 | -6.78 | -9.06 | -6.48 | -8.22 | |
Earnings yield | -0.17 | -0.18 | -0.2 | -0.24 | -0.19 | |
Free cash flow yield | -0.13 | -0.12 | -0.1 | -0.13 | -0.12 | |
Debt to equity | 0.09 | 0.09 | 0.08 | 0.08 | 0.1 | |
Debt to assets | 0.07 | 0.06 | 0.06 | 0.05 | 0.07 | |
Net debt to EBITDA | 1.25 | 1.05 | 0.36 | 0.79 | 0.18 | |
Current ratio | 1.68 | 1.31 | 0.89 | 0.92 | 0.79 | |
Interest coverage | -538.17 | -387.67 | 756.5 | -2.29K | 206.86 | |
Income quality | 0.71 | 0.66 | 0.52 | 0.52 | 0.62 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.03 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0.71 | 0 | 0 | 0 | |
Intangibles to total assets | 0.59 | 0.64 | 0.7 | 0.68 | 0.69 | |
Capex to operating cash flow | 0.05 | 0.03 | 0.01 | 0.03 | 0.03 | |
Capex to revenue | -0.05 | -0.02 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.31 | -0.14 | -0.06 | -0.08 | -0.06 | |
Stock based compensation to revenue | 0.33 | 0.17 | 0.16 | 0.1 | 0.1 | |
Graham number | 31.41 | 25.5 | 26.81 | 22.08 | 14.76 | |
ROIC | -0.15 | -0.13 | -0.19 | -0.14 | -0.07 | |
Return on tangible assets | -0.33 | -0.3 | -0.52 | -0.37 | -0.24 | |
Graham Net | 0.79 | -0.49 | -1.84 | -1.54 | -2.19 | |
Working capital | 3.01M | 1.35M | -506K | -373K | -1.15M | |
Tangible asset value | 4.25M | 2.6M | 695K | 798K | -54K | |
Net current asset value | 2.13M | 573K | -1.2M | -1.03M | -1.74M | |
Invested capital | 0.09 | 0.09 | 0.08 | 0.08 | 0.1 | |
Average receivables | 1.04M | 995.5K | 947K | 871K | 1.18M | |
Average payables | 2.34M | 2.09M | 2.12M | 2.3M | 2.46M | |
Average inventory | 652.5K | 685.5K | 627K | 541.5K | 586.5K | |
Days sales outstanding | 38.8 | 39 | 27.41 | 22.52 | 35.71 | |
Days payables outstanding | 107.86 | 102.5 | 95.31 | 99.99 | 122.06 | |
Days of inventory on hand | 33.54 | 35.54 | 23.76 | 22.35 | 30.89 | |
Receivables turnover | 2.32 | 2.31 | 3.28 | 4 | 2.52 | |
Payables turnover | 0.83 | 0.88 | 0.94 | 0.9 | 0.74 | |
Inventory turnover | 2.68 | 2.53 | 3.79 | 4.03 | 2.91 | |
ROE | -0.17 | -0.14 | -0.21 | -0.16 | -0.11 | |
Capex per share | -0.1 | -0.05 | -0.02 | -0.03 | -0.02 |
PRPO Frequently Asked Questions
What is Precipio, Inc. stock symbol ?
Precipio, Inc. is a US stock , located in New haven of Ct and trading under the symbol PRPO
What is Precipio, Inc. stock quote today ?
Precipio, Inc. stock price is $6.7 today.
Is Precipio, Inc. stock public?
Yes, Precipio, Inc. is a publicly traded company.